{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:38:39Z","timestamp":1771328319943,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.medj.2025.100779","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T14:41:50Z","timestamp":1754664110000},"page":"100779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tecovirimat at a crossroads: What the PALM007 trial tells us"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3996-8663","authenticated-orcid":false,"given":"Olivier","family":"Segeral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Calmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100779_bib1","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJMoa2412439","article-title":"Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo","volume":"392","author":"Ali","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100779_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1705688","article-title":"Oral Tecovirimat for the Treatment of Smallpox","volume":"379","author":"Grosenbach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100779_bib3","unstructured":"NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain | National Institutes of Health (NIH). https:\/\/www.nih.gov\/news-events\/news-releases\/nih-study-finds-tecovirimat-was-safe-did-not-improve-mpox-resolution-or-pain."},{"key":"10.1016\/j.medj.2025.100779_bib4","series-title":"ACTG Presents Data from Mpox Study STOMP at CROI","year":"2025"},{"key":"10.1016\/j.medj.2025.100779_bib5","article-title":"Tecovirimat for the treatment of mpox: UNITY investigators announce trial will continue as planned, with top-line results expected mid-2025","author":"Rouger","year":"2025","journal-title":"MPX Response"},{"key":"10.1016\/j.medj.2025.100779_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1128\/AAC.01596-08","article-title":"ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification","volume":"53","author":"Jordan","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medj.2025.100779_bib7","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.00021-09","article-title":"Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246","volume":"53","author":"Huggins","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medj.2025.100779_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002249","article-title":"Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection","volume":"21","author":"Nguyen","year":"2023","journal-title":"PLoS Biol."},{"key":"10.1016\/j.medj.2025.100779_bib9","unstructured":"Enrollment Starts in Africa CDC-LED Mpox Therapeutic Study (MOSA) Africa CDC. https:\/\/africacdc.org\/news-item\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/."},{"key":"10.1016\/j.medj.2025.100779_bib10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/s41591-023-02393-6","article-title":"The international Unity study for antivirals against mpox is a blueprint for future epidemics","volume":"29","author":"Telford","year":"2023","journal-title":"Nat. Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025002065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025002065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T22:39:44Z","timestamp":1756247984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025002065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2666634025002065"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100779","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tecovirimat at a crossroads: What the PALM007 trial tells us","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100779"}}